Myeloid Malignancies
📧 Sign up to get email alerts when something new happens for Myeloid Malignancies.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Germline Testing for Predisposition to Myeloid Malignancies [NA]
Ongoing recruitment for a germline genetic testing study aimed at identifying predisposition to myeloid malignancies.
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Telehealth Advance Care Planning Intervention [NA]
An ongoing clinical trial at the University of Rochester is evaluating a telehealth advance care planning intervention for myeloid malignanc…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories [NA]
A clinical trial update exploring how digital stories can help patients reflect on choosing allogeneic hematopoietic cell transplantation fo…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies [Phase 2]
A Phase 2 clinical trial evaluating a reduced MBF regimen for patients 55 years and older with myeloid malignancies, currently recruiting an…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies [Phase 1, Phase 2]
This clinical trial update describes an ongoing Phase 1/2 study of CAR.70-engineered IL15-transduced cord blood-derived NK cells with TGFBR2…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies [Phase 2]
Phase II open-label study evaluating olutasidenib as post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies [Phase 1]
A Phase 1 clinical trial update for a study of novel anti-leukemia agents used in Flu/Mel reduced-intensity conditioning transplant for myel…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML [Phase 1, Phase 2]
This clinical trial update reports that Lisaftoclax (APG-2575) is being studied as a single agent and in combination for relapsed/refractory…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: A Study of GLB-001 in Patients With Myeloid Malignancies [Phase 1]
A Phase 1 clinical trial evaluating GLB-001 in patients with myeloid malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-04Clinical Trial Update: VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT [Phase 2, Phase 3]
A Phase 2/Phase 3 trial update evaluating venetoclax plus decitabine with a Busulfan/Fludarabine conditioning regimen (Bu2Flu4) versus Bu2Fl…
-
CLINICAL_TRIALS research · 2025-06-29Clinical Trial Update: HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML [Phase 1]
Phase 1 clinical trial update for GTB-3650 Trike in high-risk myeloid malignancies, including acute myeloid leukemia and myelodysplastic syn…
-
CLINICAL_TRIALS research · 2025-04-08Clinical Trial Update: Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies [Phase 1, Phase 2]
An exploratory Phase 1/2 clinical study evaluating the safety and efficacy of CAR-T cell therapy for relapsed/refractory myeloid malignancie…
-
CLINICAL_TRIALS research · 2024-08-09Clinical Trial Update: Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. [Phase 2]
Phase 2 clinical trial evaluating a hypomethylating agent in combination with venetoclax after allogeneic stem cell transplantation in high-…